secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001437749-26-001049
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene reports CNM-Au8 biomarker data supporting potential accelerated approval; FDA meeting in Q1 2026
--------------------------------------------------------------------------------

- FDA granted in-person Type C meeting in Q1 2026 to discuss CNM-Au8 regulatory path for ALS.
- New analyses across ALS cohorts show ~10% NfL reduction associated with 8-13% lower mortality risk.
- In HEALEY trial, IGFBP7 responders to CNM-Au8 30mg had 78% mortality risk reduction (HR 0.22, p=0.01).
- CNM-Au8 consistently reduced NfL: HEALEY Week 24 GMR 0.905 (p=0.04) and NIH EAP Week 36 AUC diff -0.090 (p=0.037).
- Genetic variant linked to lower IGFBP7 expression correlates with ALS reversals, supporting CNM-Au8 mechanism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926001049/0001437749-26-001049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926001049/clnn20260109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-001049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer